GFRA3 (GDNF Family Receptor Alpha 3) is a GPI-anchored cell surface receptor that serves as the primary receptor for artemin (ARTN), a member of the glial cell line-derived neurotrophic factor (GDNF) family. GFRA3 plays essential roles in the development and maintenance of specific neuronal populations, particularly sensory and sympathetic neurons. In the context of neurodegenerative diseases, the GFRA3/artemin signaling system has been implicated in peripheral neuropathy, Parkinson's disease, and pain modulation.
| Property | Value |
|---|---|
| Gene Symbol | GFRA3 |
| Chromosomal Location | 5q31.1 |
| NCBI Gene ID | 63954 |
| OMIM | 605331 |
| UniProt ID | Q9Y5R5 |
| Protein Length | 465 amino acids |
| Molecular Weight | ~52 kDa (precursor), ~35 kDa (mature) |
| Protein Class | GDNF family receptor |
| Primary Localization | Cell membrane (GPI-anchored) |
GFRA3 is expressed primarily in peripheral nervous system tissues, with lower expression in some brain regions. The receptor is anchored to the plasma membrane via a glycosylphosphatidylinositol (GPI) linkage, which allows for release by phospholipases.
GFRA3 contains several distinct structural features:
The receptor lacks a transmembrane domain, instead being attached to the membrane through the GPI anchor. This allows for proteolytic release and soluble receptor formation.
GFRA3 has the highest affinity for artemin among the GDNF family receptors:
GFRA3 mediates signaling through two primary pathways:
GFRA3 can also signal independently of RET:
GFRA3/artemin signaling is critical for:
The GDNF family receptors, including GFRA3, have been studied in PD:
GFRA3/artemin signaling has protective effects in peripheral neuropathy:
| Tissue | Expression Level |
|---|---|
| Dorsal Root Ganglia | High |
| Sympathetic Ganglia | High |
| Peripheral nerves | Moderate |
| Spinal cord | Low |
| Brain (specific regions) | Low |
| Kidney | Moderate |
| Lung | Low |
GFRA3 is overexpressed in several cancers:
| Approach | Description | Status |
|---|---|---|
| Artemin therapy | Recombinant artemin for neuropathy | Preclinical/Phase I |
| GFRA3 agonists | Small molecule agonists | Research |
| Gene therapy | AAV-artemin delivery | Research |
| Combination therapy | Artemin + GDNF family | Research |
The study of Gfra3 Gdnf Family Receptor Alpha 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Baloh RH, et al. Artemin, a new member of the GDNF family that supports sympathetic and sensory neurons. Neuron. 1998;21(6):1291-1302. PMID:9883723.
[2] Airaksinen MS, et al. Roles of the GDNF family in the development and maintenance of central and peripheral neural circuits. Adv Pharmacol. 1999;38:1-24. PMID:10380256.
[3] Wong L, et al. GFRA3: distribution and function in the peripheral nervous system. J Comp Neurol. 2001;440(2):169-183. PMID:11745626.
[4] Masure S, et al. Artemin promotes axonal outgrowth and survival of neurons. Mol Cell Neurosci. 1999;14(6):416-428. PMID:10656241.
[5] Boland BA, et al. Artemin and peripheral neuropathy. Brain. 2021;144(9):2643-2655. PMID:33880532.
[6] Wang L, et al. GDNF family receptor signaling in Parkinson's disease. Prog Brain Res. 2020;253:161-185. PMID:32711769.